Related Experiment Videos
Pentoxifylline: a potential therapy for chronic kidney disease
Shuei-Liong Lin1, Yung-Ming Chen, Wen-Chih Chiang
1Department of Internal Medicine, National Taiwan University Hospital and Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Nephrology (Carlton, Vic.)
|September 15, 2004
Summary
Pentoxifylline shows promise in reducing proteinuria for chronic kidney disease patients, particularly those with diabetes or membranous nephropathy. Further research is needed to confirm its long-term renal benefits alongside existing therapies.
Area of Science:
- Nephrology
- Pharmacology
- Fibrosis Research
Background:
- Chronic kidney disease (CKD) progression to end-stage renal disease is marked by fibrosis.
- Current interventions like glycemic control, blood pressure management, protein restriction, and angiotensin II blockade slow CKD progression but don't halt it.
- Multidrug approaches are needed to address CKD's complexity and halt disease progression.
Purpose of the Study:
- To evaluate the potential of pentoxifylline as an adjunct therapy for chronic kidney disease.
- To assess pentoxifylline's efficacy in reducing proteinuria and its impact on renal outcomes.
Main Methods:
- Review of animal and cellular studies on pentoxifylline's anti-fibrotic, anti-inflammatory, and anti-proliferative effects.
- Analysis of limited human studies investigating pentoxifylline's effect on proteinuria in diabetic nephropathy, nephrotic syndrome, and membranous nephropathy.
Main Results:
- Animal and cellular studies support pentoxifylline's rationale for treating various CKD types.
- Human studies indicate pentoxifylline reduces proteinuria in patients on ACE inhibitors and those with refractory nephrotic syndrome.
- Monotherapy with pentoxifylline significantly reduces proteinuria in membranous nephropathy patients.
Conclusions:
- Pentoxifylline demonstrates potential in managing proteinuria in specific CKD populations.
- Further clinical trials are necessary to determine if pentoxifylline improves renal outcomes when combined with established CKD interventions.